Why These Five Stocks Are in Spotlight on Monday

Kingold Jewelry Posts Impressive Earnings Report

 Kingold Jewelry Inc (NASDAQ:KGJI)’s stock has soared by over 8% so far today as the company continues to get traders’ attention after posting second-quarter EPS of $0.30 on revenue of $390.3 million, better than last quarter’s earnings of $0.01 a share on $249.4 million revenue. The China-based jewelry company reiterated its guidance of 50-60 metric tons of 24-karat gold processed in 2016. Kingold Jewelry’s CEO Zhihong Jia said in a statement that the company’s financial results got a boost due to a rebound in prices and increasing demand in China. During the second quarter, Ken Griffin’s Citadel Advisors closed its position in Kingold Jewelry, while Renaissance Technologies increased its stake by 48% to 34,900 shares.

Aurinia Pharmaceuticals Getting Battered

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s stock is getting hammered today and is down by over 55% after the company posted overall positive top-line results of Phase 2b of its clinical trial, Voclosporin, but said there were 13 deaths across the trial. The deaths during the trial were assessed by the study investigator, and they were found to be unrelated to study treatment, said Aurinia. Nevertheless, the drug met its primary efficacy endpoint in patients with active lupus nephritis (LN), an inflammation of the kidney caused by the autoimmune disorder systemic lupus erythematosus. The Canadian biopharmaceutical company said in a statement that it plans to meet with the FDA in the fourth quarter of 2016 to discuss these the results and path towards registration of the treatment. Renaissance Technologies reported ownership of 41,100 shares of Aurinia Pharmaceuticals in its 13F filing for the end of June.

Disclosure: none